Investigational drug · Phase 2
PALI-2108
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "PALI-2108"
First trial start
2026
Aug 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PALI-2108", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis (UC)
- Severe Ulcerative Colitis
- Moderate Ulcerative Colitis
Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "PALI-2108" as an intervention, largest first.
- A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Palisade BioIndustry
NCT07845487 · 204 participants (planned) · Start Aug 28, 2026 · Primary completion Oct 2027
Drug: PALI-2108; PALI-2108 and 1 more · For: Ulcerative Colitis (UC); Severe Ulcerative Colitis; Moderate Ulcerative Colitis
Sites: Sun City, Arizona; San Diego, California; Bristol, Connecticut · 114 sites in all
Palisade BioIndustry
NCT06663605 · 89 participants · Start Nov 5, 2024 · Primary completion Jul 7, 2025
Drug: PALI-2108; PALI-2108 Placebo · For: Ulcerative Colitis (UC); Healthy Volunteer
Sites: Montreal, Canada
- A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's DiseaseActive, not recruiting
Palisade BioIndustry
NCT07428096 · 6 participants (planned) · Start Oct 17, 2025 · Primary completion Jan 30, 2026
Drug: PALI-2108 · For: Fibrostenotic Crohn's Disease
Sites: Montreal, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ulcerative Colitis (UC)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- anti-TL1A monoclonal antibodyPhase 22 trials
Biocad · Ulcerative Colitis (UC), Crohn's Disease (CD)
- HSK47388Phase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)
- INT-210Phase 21 trial
Innatus Therapeutics (Shanghai) Co., Ltd. · Ulcerative Colitis (UC)
- MB-001Phase 21 trial
Mage Biologics · Ulcerative Colitis (UC)
- MGT-006Phase 21 trial
Metagen Therapeutics, Inc. · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
- MT-201Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.